Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
C4 Therapeutics, Inc. (CCCC) had Free Cash Flow per Share of $-1.20 for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$11.02M |
|
$-20.49M |
|
-- |
|
$11.02M |
|
$34.16M |
|
$-23.14M |
|
$2.78M |
|
$-20.36M |
|
$-20.36M |
|
$-20.49M |
|
$-20.49M |
|
$-20.49M |
|
$-20.49M |
|
$-23.14M |
|
$-23.58M |
|
82.89M |
|
82.89M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$258.11M |
|
$4.74M |
|
$100.97M |
|
$359.07M |
|
$33.03M |
|
-- |
|
$69.46M |
|
$102.49M |
|
$256.59M |
|
$256.59M |
|
$256.59M |
|
96.91M |
|
| Cash Flow Statement Financials | |
$-98.69M |
|
$-8.60M |
|
$126.40M |
|
$58.94M |
|
$78.05M |
|
$19.10M |
|
$19.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.81 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-210.10% |
|
-210.10% |
|
-- |
|
-184.87% |
|
-185.97% |
|
$-99.30M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
4.59 |
|
19.62 |
|
-7.98% |
|
-7.98% |
|
-5.71% |
|
-7.98% |
|
$2.65 |
|
|
Free Cash Flow per Share |
$-1.20 |
$-1.19 |
|